CMS has been cracking down on possible fraud with medical equipment suppliers for months, sharing two major updates in recent weeks that together define a significant CMS DMEPOS suppliers $3.4 billion fraud enforcement effort.
What the CMS DMEPOS Suppliers $3.4 Billion Fraud Announcement Actually Covers
CMS announced that it is barring 11 medical supply companies focused on durable medical equipment, prosthetics, orthotics and supplies from earning future Medicare Advantage Part C and Part D payments. In 2025 and 2026, these companies had more than $3.4 billion in suspected fraudulent billing practices, said in a Sept. 8 news release.
The Specific Fraudulent Practices CMS Identified
CMS claimed the 11 DMEPOS suppliers did not submit claims before 2025, used “improper” billing practices, billed for deceased beneficiaries’ medical equipment and supplied equipment to beneficiaries who did not request or receive it. Four of the 11 suppliers had already lost their original Medicare privileges, instead billing MA plans, a detail suggesting these suppliers may have shifted their billing activity toward Medicare Advantage specifically after losing traditional Medicare access.
The Moratorium Behind This CMS DMEPOS Suppliers $3.4 Billion Fraud Crackdown
Just weeks prior, a six-month Medicare enrollment moratorium affecting some DMEPOS suppliers expired Aug. 27, according to CMS. The moratorium, which went into effect Feb. 27 and addressed fee-for-service Medicare, was part of CMS’s sweeping healthcare fraud initiatives. Just a few months later, also imposed a six-month freeze on new Medicare enrollments for hospices and home health agencies.
Why the Moratorium’s Expiration Doesn’t Signal the Crackdown Is Ending
The agency can extend moratoria in six-month increments. However, confirmed national provider enrollment contractors have resumed accepting initial enrollment applications from these DMEPOS suppliers. This resumption of new enrollment applications, occurring in the same window as the announcement barring 11 existing suppliers over $3.4 billion in suspected fraud, illustrates how CMS is simultaneously reopening the door to new, presumably compliant suppliers while tightening enforcement against those already flagged for fraudulent conduct.
What CMS Is Telling Suppliers About the 2028 Competitive Bidding Program
The agency encouraged suppliers planning to bid in DMEPOS Competitive Bidding Program Round 2028 to “submit any completed enrollment applications as soon as possible,” allowing contractors sufficient time to review applications before the bidding window.
A Related Change to Bid Surety Bond Requirements
As established by the 2027 Inpatient Rehabilitation Facilities Prospective Payment System Final Rule, CMS elevated the required bid surety bond amount from $50,000 to $100,000 for bids submitted under a Remote Item Delivery Competitive Bidding Program. The RID competitive bidding area will be nationwide as well, meaning this doubled bond requirement will apply broadly across the entire program rather than to a limited subset of suppliers or regions.
How This Fits CMS’s Broader 2026 Fraud Enforcement Pattern
This DMEPOS crackdown adds to a broader wave of fraud enforcement throughout 2026, including the earlier freeze on new hospice and home health enrollments and separate lab payment fraud prevention efforts that blocked more than $1.6 billion in potentially improper Medicare payments.
Why Raising Bond Requirements Alongside Fraud Enforcement Makes Sense
Pairing increased financial accountability measures, like the doubled bid surety bond, with active enforcement against suppliers already engaged in fraudulent billing suggests CMS is pursuing a dual strategy: raising the financial barrier to entry for new suppliers while simultaneously removing bad actors already operating within the system.
What This CMS DMEPOS Suppliers $3.4 Billion Fraud Crackdown Means Going Forward
With enrollment applications now reopened following the moratorium’s expiration and the bid surety bond requirement doubled, DMEPOS suppliers planning to participate in the 2028 Competitive Bidding Program should prepare for both stricter financial requirements and continued scrutiny of their billing practices. Given that four of the 11 barred suppliers had already lost original Medicare privileges before shifting to Medicare Advantage billing, this case may prompt CMS to examine whether other suppliers previously excluded from traditional Medicare are similarly attempting to continue operating through MA plans.
What to Watch Going Forward
As DMEPOS suppliers submit new enrollment applications ahead of the 2028 Competitive Bidding Program, industry observers will likely watch whether CMS’s enhanced scrutiny and higher bond requirements meaningfully reduce fraudulent billing activity within this supplier category going forward. Given the scale of this CMS DMEPOS suppliers $3.4 billion fraud finding, this crackdown may signal continued aggressive federal enforcement across the broader durable medical equipment supply chain as CMS works to close the gaps that allowed these suppliers to bill more than $3.4 billion in suspected fraudulent claims across both fee-for-service Medicare and Medicare Advantage programs.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
